All news
News
Press
Publications
BRCA1/2 variants are prognostic biomarkers for hereditary breast and/or ovarian cancer (HBOC) syndrome and predictive biomarkers for PARP inhibition.
Blanca Baez in an interview with US magazine CIO Applications on how to make unbiased clinical development and portfolio decisions with MH Predict.
Dear customers and partners,
at Molecular Health we share the global concern over the coronavirus pandemic. We want to assure you that we will maintain uninterrupted operation during these challenging times.
Strongly mutated tumors are more likely to generate neoantigens that are recognized as foreign by immune cells. Tumors with a high TMB can therefore have a high immunogenicity.
Molecular Health is featured in a case study of DrugBank, the world’s largest online database of drug and drug target information.
Each cancer diagnosis is unique, so individualized treatment is critical. With its Molecular Health Guide (MH Guide) powered by SAP HANA®, Molecular Health is transforming cancer treatment.
The molecular characterization of patient tumors provides a rational and highly promising approach for guiding…
Heidelberg, Germany – May 31, 2019 – Molecular Health (MH), a leading company in the field of…
Heidelberg, Germany – Tuesday, May 7, 2019–Molecular Health, a leading company in the field of…
Blanca Baez in an interview with US magazine CIO Applications on how to make unbiased clinical development and portfolio decisions with MH Predict.
Dear customers and partners,
at Molecular Health we share the global concern over the coronavirus pandemic. We want to assure you that we will maintain uninterrupted operation during these challenging times.
Strongly mutated tumors are more likely to generate neoantigens that are recognized as foreign by immune cells. Tumors with a high TMB can therefore have a high immunogenicity.
Molecular Health is featured in a case study of DrugBank, the world’s largest online database of drug and drug target information.
Each cancer diagnosis is unique, so individualized treatment is critical. With its Molecular Health Guide (MH Guide) powered by SAP HANA®, Molecular Health is transforming cancer treatment.
Molecular Health is sponsor and exhibitor at the 103rd Annual Meeting of the German Society…
Benefit from our software-aided interpretations for personalized cancer treatment
• Latest and comprehensive clinical evidence…
Clinical trials can fail to detect rare adverse events (AEs). We assessed the ability of…
• MH Mendel combines the most relevant information for the diagnosis of hereditary diseases
• MH Mendel…
Heidelberg, Germany – May 31, 2019 – Molecular Health (MH), a leading company in the field of…
Heidelberg, Germany – Tuesday, May 7, 2019–Molecular Health, a leading company in the field of…
Molecular Health Guide (MH Guide) shortlisted forthe German Digital Health Award 2019
• Novartis and Sandoz…
• Molecular Health Predict enables highly accurate estimates of clinical trial success probabilities
• Exclusive license for…
Heidelberg, Germany and Boston, USA – July 3, 2018 – Molecular Health (MH), a leading biomedical company…
New features for intuitive biomarker classification and improved usability
Heidelberg, Germany and Boston, USA – June…
Molecular Health receives grant from Bill & Melinda Gates Foundation
Heidelberg, Germany/Boston, MA, May 16…
As it gains a foothold in international markets, Molecular Health will be demonstrating its latest…
New features for intuitive biomarker classification and improved usability
Heidelberg, Germany and Boston, USA – June…
BRCA1/2 variants are prognostic biomarkers for hereditary breast and/or ovarian cancer (HBOC) syndrome and predictive biomarkers for PARP inhibition.
The molecular characterization of patient tumors provides a rational and highly promising approach for guiding…
Adverse Event Circumstances and the Case of Drug Interactions…
Peter Schotland, Rebecca Racz, David Jackson, Robert Levin, David G. Strauss and Keith Burkhart…
We present a novel approach for the molecular transformation and analysis of patient clinical phenotypes…
Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event…
Racz, Soldatos, Jackson, Burkhart. Clin Transl Sci (2018) 00, 1–8; doi:10.1111/cts.12543…
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with an extremely poor prognosis, predominantly as a…
Bohnert, Vivas, Jansen https://doi.org/10.1371/journal.pone.0186175…
To find out more, you can call our customer service or send us an e-mail. We would be delighted to provide you with more information or answer your questions.
